Daniel J. Becker, MD | Authors

THOMPSON PHARMACY & MEDICAL

326 OX BOW TRL

Articles

The Time for Low-Dose Computed Tomography Screening Is Now: A Medical Oncologist Perspective

November 15, 2014

The NLST is a landmark trial demonstrating that implementation of low-dose CT screening lowers lung cancer–related mortality. We must put the study results and cost-effectiveness analyses in the context of the staggering statistics: up to 65% of lung cancer patients present with advanced-stage disease where treatments are often costly, toxic, and only palliative in nature.